← All trials
NCT04677439
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2021
- Primary completion
- May 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- Dec 21, 2020
- Last posted
- Dec 29, 2020
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Medical UniversityLead sponsor
- Peking UniversityCollaborator
- China Medical UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Hainan People's HospitalCollaborator
- Shantou UniversityCollaborator
- Sanya Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.